Literature DB >> 2847384

Histopathological characterization of a novel monoclonal antibody, MLuC1, reacting with lung carcinomas.

R Agresti1, R Alzani, S Andreola, V Bedini, S Gianì, S Ménard, F Rilke, M I Colnaghi.   

Abstract

A monoclonal antibody (MoAb), MLuC1, derived from the fusion of P3-X63-Ag 8-U1 mouse myeloma cells with spleen cells from an HR mouse immunized with the carcinoma cell line SW626, was studied to define its reactivity profile on normal and neoplastic human tissues and its potential clinical applications in lung cancer. Evaluation of paraffin sections using the ABC immunoperoxidase method showed a "pan-epithelial" reactivity; a large majority of epithelial components of organs in the respiratory, digestive and urogenital systems (except liver, rectum and ovary) were immunostained. As regard to neoplastic tissues MLuC1 recognized 84% of lung carcinomas (82% of small cell, 100% of squamous cell, 74% of adenocarcinomas), 86% of breast and 62% of ovarian carcinomas. On the contrary, MLuC1 was non-reactive with the other normal and tumoral non-epithelial tissues. Due to its spectrum of reactivity this MoAb could be useful for different diagnostic purposes such as differential diagnosis and lung cancer cytology.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847384     DOI: 10.1177/030089168807400406

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  An efficient method for culturing human breast carcinoma to evaluate antiblastic drug activity in vitro: experience on 136 primary cancers and on 116 recurrences.

Authors:  W Zoli; A Volpi; C Bonaguri; A Riccobon; S Savini; R Brizio; A Saragoni; L Medri; G A Marra; D Amadori
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

2.  Establishment and characterization of a new cell line from primary human breast carcinoma.

Authors:  D Amadori; L Bertoni; A Flamigni; S Savini; C De Giovanni; S Casanova; F De Paola; A Amadori; E Giulotto; W Zoli
Journal:  Breast Cancer Res Treat       Date:  1993-12       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.